However, the TP53-loss phenocopy signature is clearly associated with neoadjuvant chemotherapy response in breast cancer across multiple clinical cohorts comprising nearly 4000 patients, including patients treated with chemoimmunotherapy. This evidence concerns the gene TP53 and breast carcinoma.